Cell MedX (Cell MedX) Operating Income : $-0.22 Mil (TTM As of Feb. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Cell MedX Operating Income?

Cell MedX's Operating Income for the three months ended in Feb. 2024 was $-0.06 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.22 Mil.

Warning Sign:

Cell MedX Corp has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. Cell MedX's Operating Income for the three months ended in Feb. 2024 was $-0.06 Mil. Cell MedX's Revenue for the three months ended in Feb. 2024 was $0.00 Mil. Therefore, Cell MedX's Operating Margin % for the quarter that ended in Feb. 2024 was %.

Cell MedX's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cell MedX's annualized ROC % for the quarter that ended in Feb. 2024 was -34.24%. Cell MedX's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was %.

Cell MedX Operating Income Historical Data

The historical data trend for Cell MedX's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell MedX Operating Income Chart

Cell MedX Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Operating Income

Get a 7-Day Free Trial

-0.67

-1.04

-0.68

-0.67

-0.45

Cell MedX Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Operating Income	Get a 7-Day Free Trial															-0.11	-0.07	-0.05	-0.04	-0.06

Cell MedX Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.22 Mil.

Cell MedX (OTCPK:CMXC) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cell MedX's annualized ROC % for the quarter that ended in Feb. 2024 is calculated as:

	ROC % (Q: Feb. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Nov. 2023 )	+	Invested Capital (Q: Feb. 2024 ))	/ count )
=	-0.232 * ( 1 - 0% )	/	( (1.033	+	0.322)	/ 2 )
=	-0.232	/	0.6775
=	-34.24 %

where

	Invested Capital		(Q: Nov. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.023	-	1.515	-	( 0.023	-	max(0, 2.548	-	0.023	+	0.023	))
=	1.033

	Invested Capital		(Q: Feb. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.082	-	0.47	-	( 0.08	-	max(0, 0.792	-	0.082	+	0.08	))
=	0.322

Note: The Operating Income data used here is four times the quarterly (Feb. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Cell MedX's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Feb. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Nov. 2023		Q: Feb. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	0.52	/	( ( (0 + max(-1.515, 0))	+	(0 + max(-0.469, 0)) )	/	2 )
=	0.52	/	( ( 0	+	0 )	/	2 )
=	0.52	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Nov. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(1.515	+	0	+	0)
=	-1.515

	Working Capital		(Q: Feb. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.001)	-	(0.47	+	0	+	0)
=	-0.469

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Cell MedX's Operating Margin % for the quarter that ended in Feb. 2024 is calculated as:

Operating Margin %	=	Operating Income (Q: Feb. 2024 )	/	Revenue (Q: Feb. 2024 )
	=	-0.058	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Cell MedX Operating Income Related Terms

Thank you for viewing the detailed overview of Cell MedX's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Cell MedX (Cell MedX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cell MedX Corp (OTCPK:CMXC) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

123 W. Nye Lane, Suite 446, Carson City, NV, USA, 89706

Website

https://www.cellmedx.com

Cell MedX Corp is an early stage development company focused on the discovery, development and, commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage the illness and related complications. The company's product portfolio consists of electromedical technologies, ebalance, and others.

Executives

Richard Jeffs	10 percent owner	FLAT 7, 6 ENNISMORE GARDENS, LONDON X0 SW7 1NL
Dwayne Yaretz	director, officer: Chief Executive Officer	SUITE 1050 WEST PENDER STREET SUITE 2250, VANCOUVER A1 V6E 3S7
Bradley S Hargreaves	10 percent owner	904-1616 BAYSHORE DR, VANCOUVER A1 V6G3L1
Frank Mcenulty	director, officer: CEO, CFO, Treas., Sec	4182 N. VIKING WAY, SUITE 216, LONG BEACH CA 90808-1475
Joao Dacosta	director, officer: COO	#810 - 789 WEST PENDER STREET, VANCOUVER A1 V6C 1H2
George Adams	director	7535 CONSERVATION ROAD, GUELPH A6 N1H6J1
Terrance George Owen	director, officer: CEO	635 FOURTH LINE (UNIT 1), OAKVILLE A6 L6L 5BO
John David Sanderson	officer: Chief Medical Officer	9 ISLANDVIEW, IRVINE CA 92604
Yanika S Silina	officer: CFO, Treasurer and Secretary	789 WEST PENDER STREET, UNIT 810, VANCOUVER A1 V6C 1H2
Jean M Arnett	10 percent owner	121 - 3989 HENNING DRIVE, BURNABY A1 V5C 6P8
Ean Kremer	director, officer: Chief Technology Officer	C/O PLANDEL RESOURCES, INC., 4575 DEAN MARTIN DRIVE, STE. 2206, LAS VEGAS NV 89103

Cell MedX (Cell MedX) Headlines

From GuruFocus

Cell MedX Insider Buys 22,500 Shares

By Kyle Ferguson Kyle Ferguson • 11-11-2016